Insider Selling: ADMA Biologics (NASDAQ:ADMA) Director Sells $139,200.00 in Stock

ADMA Biologics Inc (NASDAQ:ADMA – Get Free Report) Director Lawrence Guiheen sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $13.92, for a total value of $139,200.00. Following the completion of the transaction, the director owned 63,599 shares of the company’s stock, valued at approximately $885,298.08. This represents a 13.59% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

ADMA Biologics Stock Down 1.6%

NASDAQ:ADMA traded down $0.22 during trading hours on Monday, hitting $13.46. The stock had a trading volume of 3,050,514 shares, compared to its average volume of 4,078,892. The company has a market cap of $2.99 billion, a PE ratio of 17.19 and a beta of 0.65. The business has a 50 day simple moving average of $10.65 and a two-hundred day simple moving average of $10.77. ADMA Biologics Inc has a 1-year low of $7.21 and a 1-year high of $20.46. The company has a current ratio of 6.04, a quick ratio of 3.25 and a debt-to-equity ratio of 0.45.

ADMA Biologics (NASDAQ:ADMA – Get Free Report) last posted its earnings results on Wednesday, November 4th. The biotechnology company reported $0.23 EPS for the quarter, topping analysts’ consensus estimates of $0.20 by $0.03. The business had revenue of $141.10 million for the quarter, compared to analysts’ expectations of $138.11 million. ADMA Biologics had a net margin of 35.14% and a return on equity of 42.56%. The business’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same period in the previous year, the company posted $0.15 earnings per share. Analysts predict that ADMA Biologics Inc will post 0.82 EPS for the current year.

Wall Street Analysts Forecast Growth

ADMA has been the subject of several recent analyst reports. Mizuho set a $18.00 target price on ADMA Biologics in a research note on Thursday, November 5th. Cantor Fitzgerald boosted their price target on ADMA Biologics from $12.00 to $13.00 and gave the stock a “neutral” rating in a research note on Thursday, November 5th. Zacks Research raised ADMA Biologics from a “strong sell” rating to a “hold” rating in a report on Wednesday, September 2nd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a research note on Monday, September 14th. Three equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, ADMA Biologics has an average rating of “Moderate Buy” and a consensus target price of $17.50.

Read Our Latest Research Report on ADMA

Institutional Trading of ADMA Biologics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. NorthCrest Asset Manangement LLC increased its holdings in shares of ADMA Biologics by 8.4% in the 3rd quarter. NorthCrest Asset Manangement LLC now owns 15,952 shares of the biotechnology company’s stock valued at $165,000 after acquiring an additional 1,234 shares during the last quarter. Allspring Global Investments Holdings LLC increased its holdings in shares of ADMA Biologics by 4.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 32,087 shares of the biotechnology company’s stock worth $319,000 after acquiring an additional 1,316 shares during the period. Pinnacle Wealth Planning Services Inc. raised its holdings in shares of ADMA Biologics by 33.1% during the third quarter. Pinnacle Wealth Planning Services Inc. now owns 5,721 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 1,422 shares during the last quarter. CenterBook Partners LP increased its position in ADMA Biologics by 1.8% in the 3rd quarter. CenterBook Partners LP now owns 81,607 shares of the biotechnology company’s stock valued at $819,000 after acquiring an additional 1,432 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in ADMA Biologics by 0.4% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 395,356 shares of the biotechnology company’s stock valued at $3,309,000 after acquiring an additional 1,705 shares in the last quarter. Institutional investors own 75.68% of the company’s stock.

About ADMA Biologics

(Get Free Report)

ADMA Biologics is a biopharmaceutical company that develops, manufactures and markets plasma-derived therapies for people with immune deficiencies and certain infectious diseases. Its products include BIVIGAM and ASCENIV, intravenous immune globulin therapies used to treat primary humoral immunodeficiency, and Nabi-HB, an immune globulin used for hepatitis B prevention in specific clinical settings. The company collects human plasma through its U.S. donor centers and processes it into therapies at its manufacturing facility in Boca Raton, Florida.

Recommended Stories

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.